Golden Week For Daiichi: Damages Due From Ranbaxy Brothers
Executive Summary
In what seems like some consolation for Daiichi Sankyo after its disastrous acquisition of Ranbaxy Laboratories and subsequent divestment of the Indian company, arbitration proceedings in Singapore against the Singh brothers of Ranbaxy have gone the Japanese firm's way.
You may also be interested in...
Daiichi set for $3.6bn cash out of Sun
Things appear to have come full circle for Daiichi Sankyo in India - at least concerning Ranbaxy.
Daiichi initiates arbitration proceedings against Singhs of Ranbaxy but is it more symbolic?
Following through on its May 22 statement, Daiichi Sankyo is said to have moved towards initiating arbitration proceedings in Singapore against the former shareholders of Ranbaxy Laboratories, the Singh brothers, over alleged misrepresentation of critical information concerning the US Department of Justice (DoJ) and FDA investigations against Ranbaxy at the time of the 2008 takeover by the Japanese company.
Ranbaxy whistleblower pockets $50M+ in $500M settlement
The $50 million-plus a former executive at Ranbaxy is walking away with is another reality check for companies that when they engage in wrongdoing, there is likely someone watching and willing to come forward.